

# City of London Corporation Committee Report

<b>Committee(s):</b> Health and Wellbeing Board – For decision	<b>Dated:</b> 19/09/2025
<b>Subject:</b>  Pharmaceutical Needs Assessment 2025-2028 Final Report	<b>Public report:</b>  For Decision
<b>This proposal:</b> <ul style="list-style-type: none"> <li>• <b>Provides statutory duties</b></li> </ul>	This report meets the Health and Wellbeing Board duty to produce a pharmaceutical needs assessment every three years, as per The NHS Act 2006.
<b>Does this proposal require extra revenue and/or capital spending?</b>	No
<b>If so, how much?</b>	N/A
<b>What is the source of Funding?</b>	N/A
<b>Has this Funding Source been agreed with the Chamberlain's Department?</b>	N/A
<b>Report of:</b>	Dr Sandra Husbands Director of Public Health
<b>Report author:</b>	Dr Andrew Trathen Consultant in Public Health

## Summary

This report seeks Health and Wellbeing Board approval for the Pharmaceutical Needs Assessment (PNA) 2025-2028. Public Health commissioned the provider *Healthy Dialogues* in early 2025 to ensure the board meets its statutory requirement to publish a PNA by 1st October 2025. With the support of a multi-stakeholder steering group, a final report has now been delivered by the provider.

## Recommendation

Members are asked to:

- Approve the draft of the City of London Pharmaceutical Needs Assessment 2025-2028 for publication.

# Main Report

## Background

1. Since 1 April 2013, every Health and Wellbeing Board (HWB) in England has had a statutory responsibility to publish and keep up to date a statement of the needs for pharmaceutical services for the population in its area.
2. The NHS Act 2006, amended by the Health and Social Care Act 2012, sets out the requirements for HWBs to develop and update a [‘Pharmaceutical Needs Assessment’](#) (PNA).
3. Following HWB approval, the current PNA was published in October 2022. The deadline for the next is 1st October 2025.
4. At the beginning of 2025, the City and Hackney Public Health team commissioned *Healthy Dialogues* as an external provider to produce the PNA. The work has been overseen by a multi-partner steering group, who first met in March to agree a Terms of Reference (ToR) and the structure and content of a public survey. The ToR is included in the PNA.
5. Subsequent meetings have supported the work through answering questions for the provider, providing data where appropriate, and appraising early drafts for the full report.

## Current Position

6. Following the mandatory two month consultation period on a full draft, Healthy Dialogues incorporated feedback into a final draft intended for publication.
7. This report is presented to the board for approval (Appendix 1).

## Options

8. N/A

## Proposals

9. The Health and Wellbeing Board are asked to approve the final draft of the PNA 2025-28.
10. Following approval, the report can be published online in good time to meet the 1st October 2025 deadline.

## Key Data

11. The PNA contains comprehensive information intended to support commissioning decisions on pharmaceutical services. The headline conclusions are:

- a. There is good access to necessary and other relevant services with no gaps in the current and future provision of these services identified.
  - b. No substantial differences were found between groups with protected characteristics or a likely higher need for services in how they access their pharmacies or what they use them for.
12. Further details on the statutory requirements of the PNA, the methods deployed and detailed findings can be found in the report itself, Appendix 1.

## **Corporate & Strategic Implications**

### ***Strategic implications***

13. The provision of pharmaceutical services is a responsibility of the NHS. However, ensuring we meet local needs supports the Corporate Plan priority to provide excellent services.

### ***Financial implications***

14. None

### ***Resource implications***

15. The work has been undertaken drawing on the public health grant for commissioning the provider, and delivered by the public health team. There are no further resource implications.

### ***Legal implications***

16. Publishing the PNA by 1st October 2025 will meet the statutory duty of the HWB to assess needs for pharmaceutical services in its area.

### ***Risk implications***

17. None

### ***Equalities implications***

18. The PNA concludes that there are no equalities implications given the provision of pharmaceutical services in the City of London, as no substantial differences were found between groups with protected characteristics or a likely higher needs for services in how they access their pharmacies or what they use them for.
19. These findings will be recorded in a separate Equalities Impact Assessment template.

### ***Climate implications***

20. None

### ***Security implications***

21. None

### **Conclusion**

22. The process of producing the PNA for 2025-2028 has now concluded, with a final report that meets all statutory requirements. This has been undertaken by a public health-commissioned provider with previous experience of delivering such reports.

23. The work has had close operational oversight by a steering group containing a wide range of locally relevant expertise. Public and professionals have had multiple opportunities to engage with the process and feed into the output, through an initial public survey and later consultation phase.

24. The board is requested to approve the final report in good time for publication before the deadline of 1st October 2025.

### **Appendices**

- Appendix 1 – Pharmaceutical Needs Assessment 2025-2028

### **Dr Andrew Trathen**

Consultant in Public Health, City and Hackney Public Health Team

T: 07940660423

E: [andrew.trathen@cityandhackneyph.hackney.gov.uk](mailto:andrew.trathen@cityandhackneyph.hackney.gov.uk)